Company Also to Host Drug-Eluting Stent Symposium and Analyst Webcast
MENLO PARK, Calif., Oct. 16 /PRNewswire-FirstCall/ -- XTENT, Inc. (Nasdaq: XTNT) today announced that 2-year data from the CUSTOM I trial and 1-year data from the CUSTOM II trial of the company's investigational Custom NX(R) drug-eluting stent (DES) system will be presented at the Cardiovascular Research Foundation's (CRF) nineteenth annual Transcatheter Cardiovascular Therapeutics (TCT) scientific symposium in Washington, D.C., which is taking place October 20 to 25.
In addition, the company will conduct a number of activities during the meeting including an analyst webcast and teleconference to review the CUSTOM I and CUSTOM II clinical data, an evening drug-eluting stent symposium, and an exhibition at booth 6097 on Level 2 of the Washington Convention Center.
Schedule of Events
Sunday, October 21
Event: The Drug-Eluting Stent Summit: The XTENT CUSTOM Biolimus-Eluting
Modular Stent Program (Focus on Multivessel and Diffuse Disease)
Pieter Stella, M.D., Director of Cardiology, University Medical Center,
Utrecht, Netherlands, will present a historical overview and current
perspective on the treatment of multivessel coronary disease and the
treatment of long lesions. An overview of the Custom NX(R) DES System with
respect to the treatment of multivessel and diffuse disease will be
discussed, along with the one-year follow-up results of the CUSTOM II
Time/Location: 3:16-3:26 p.m. EDT; Ballroom C, 3rd Floor, Washington
Event: Evening Symposium -- Delivering Safety to Today's Patients
Professor Eberhard Grube, M.D., Chief
|SOURCE XTENT, Inc.|
Copyright©2007 PR Newswire.
All rights reserved